Viridian Therapeutics’ elegrobart (VRDN-003) trial results for active thyroid eye disease drove sharp investor reaction after a pivotal Phase 3 readout showed proptosis improvements but renewed debate on competitive positioning. In Reveal-1, the subcutaneous, half-life-extended IGF-1R monoclonal antibody met the primary proptosis responder rate endpoint at the monthly dosing regimen, with responder rates higher than placebo. Meanwhile, a separate Phase 3 signal in idiopathic pulmonary fibrosis is also feeding broader respiratory risk-taking, but for Viridian, the immediate stock move highlights how even endpoint wins can leave investors focused on cross-trial comparisons and commercial feasibility. Elsewhere in oncology investing, the biotech space continued to balance catalysts and uncertainty, with market attention splitting between efficacy demonstrations and questions about differentiation against existing standards of care.